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The aryl hydrocarbon receptor interacting protein (AIP) founder mutation R304* (or p.R304*; 
NM_003977.3:c.910C>T, p.Arg304Ter)  identified in Northern Ireland (NI) predisposes to 
acromegaly/gigantism; its population health impact remains unexplored. We measured R304* 
carrier frequency in 936 Mid Ulster, 1000 Greater Belfast (both in NI) and 2094 Republic of Ireland 
(ROI) volunteers and in 116 acromegaly/gigantism patients.  Carrier frequencies were 0.0064 in Mid 
Ulster (95%CI=0.0027-0.013; p=0.0005 vs. ROI), 0.001 in Greater Belfast (0.00011-0.0047) and zero in 
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12.6%, p<0.05), but not in ROI (2/29, 6.8%) vs. non-Irish patients (0-2.41%). Haploblock conservation 
supported a common ancestor for all the 18 identified Irish pedigrees (81 carriers, 30 affected). Time 
to most recent common ancestor (tMRCA) was 2550 (1275-5000) years. tMRCA-based simulations 
predicted 432 (90-5175) current carriers, including 86 affected (18-1035) for 20% penetrance. In 
conclusion, R304* is frequent in Mid Ulster, resulting in numerous acromegaly/gigantism cases. 
tMRCA is consistent with historical/folklore accounts of Irish giants. Forward simulations predict 
many undetected carriers; geographically-targeted population screening improves asymptomatic 
carrier identification, complementing clinical testing of patients/relatives. We generated disease 
awareness locally, necessary for early diagnosis and improved outcomes of AIP-related disease. 




Germline aryl hydrocarbon receptor interacting-protein (AIP; MIM# 605555) mutations cause 
autosomal dominant familial isolated pituitary adenomas (FIPA) most commonly manifesting as 
acromegaly or gigantism. Due to incomplete penetrance, the disease can also manifest as apparently 
sporadic pituitary adenoma (PA) (Daly, et al., 2007; Leontiou, et al., 2008; Vierimaa, et al., 2006). 
These mostly GH- (somatotrophinomas) and/or prolactin-secreting tumours develop in 17-20% of 
AIP mutation (AIPmut) carriers, typically before 30 years of age (Beckers, et al., 2013; Hernández-
Ramírez, et al., 2015). A diagnostic delay of several years from onset of symptoms is typical in 
somatotrophinomas, allowing tumour expansion and prolonged GH excess, leading to significant 
complications (Reddy, et al., 2010). Despite major therapeutical advances, management of 
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two frequent characteristics of AIPmut-positive patients (Beckers, et al., 2013). Identification of 
AIPmut carriers enables earlier clinical diagnosis and treatment, improving outcomes (Hernández-
Ramírez, et al., 2015). To this end, predictive genetic testing of relatives of carriers is recommended 
(Korbonits, et al., 2012). General population screening is costly but targeted screening could be cost-
effective when a disease-associated allele is geographically highly localised (Schiavi, et al., 2012), as 
might be expected for evolutionarily recent mutations. To date, population screening for genetic 
pituitary disease has not been performed. 
We have previously inferred a recent origin for the NM_003977.3:c.910C>T (p.Arg304Ter) allele 
(p.R304* or R304*) in six FIPA pedigrees of Irish ancestry, including individuals born in the 18th and 
20th centuries, in a small region within Mid Ulster, Northern Ireland (NI) (Chahal, et al., 2011; Stals, et 
al., 2011). Using the age estimate of R304*, we predicted through forward simulations a large 
number of current carriers (Chahal, et al., 2011). Therefore, we hypothesised that R304* would be 
frequent in the Irish general population, in particular in Mid Ulster, and should lead to a high 
proportion of R304*-positive patients with somatotrophinomas. In this study, we conducted a 
population screening in Mid Ulster, in comparison with two large population samples from Greater 
Belfast, NI and from the Republic of Ireland (ROI). In addition, we identified R304* carriers among 
patients with acromegaly/gigantism in two main Irish endocrine referral centres (Belfast and Dublin) 
and studied R304*-positive patients in our International FIPA Consortium  database (Hernández-
Ramírez, et al., 2015). We developed a new coalescent-based simulation approach to more precisely 
estimate the time to most recent common ancestor (tMRCA) of the Irish R304* allele based on 
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Materials and Methods 
Subjects 
We performed a cross-sectional genetic analysis study of general population adult individuals from 
three regions in Ireland: screening of volunteers from Mid Ulster (Local Government Districts of 
Magherafelt, Cookstown and Dungannon of NI) and genotyping of two large control groups from  
the Greater Belfast region – PRIME study participants (Linden, et al., 2012) – and the ROI Trinity 
Biobank (Table 1). Sample size calculations and screening procedures are described in the Supp. 
Methods. 
A prospective cohort of unselected patients with acromegaly or gigantism were recruited at the 
University Hospital in Belfast, the only tertiary pituitary referral centre in NI (n=87, representing 60%  
of the NI Acromegaly Registry patients), and at the Beaumont Hospital, Dublin, the largest pituitary 
referral centre in ROI and closest to Mid Ulster (n=29). Additional R304*-positive pedigrees (5 Irish 
and 5 non-Irish) and 13 AIPmut-negative Irish FIPA pedigrees (Hernández-Ramírez, et al., 2015) were 
also included. Ethnicity – as assessed through family history – was unambiguous for all pedigrees. 
R304*-positive patients were previously reported (Chahal, et al., 2011; Hernández-Ramírez, et al., 
2015; Igreja, et al., 2010; Leontiou, et al., 2008; Stals, et al., 2011; Williams, et al., 2014), while the 
other patients and subjects have not been previously described. Patients were tested for AIPmuts, as 
previously described (Igreja, et al., 2010). The following pedigree codes were used: ‘Sp’ (sporadic), 
‘FIPA’ (familial) and ‘Screening’ (screening-detected). Tooth-extracted DNA from a pituitary giant’s 
skeleton at Trinity College Dublin (Cunningham, 1892) was sequenced for AIPmut, as previously 
described (Chahal, et al., 2011). The study protocol was approved by the local Ethics Committees; all 
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Evolutionary Genetics and Statistical Analysis 
Fourteen microsatellites (STR) covering 8.3 Mbp around the AIP gene were genotyped in a minimum 
of one R304* carrier per pedigree, as previously described (Chahal, et al., 2011). Haplotypes were 
computed using PHASE (Stephens, et al., 2001), incorporating phasing information deduced from 
genotypes of closely-related carriers (three pedigrees) (Supp. Table S1). To estimate the tMRCA of 
R304*-containing haplotypes, we developed a novel inference methodology combining an analytical 
result from coalescence theory and simulations in an Approximate Bayesian Computation 
framework (Beaumont, et al., 2002). First, we computed the tMRCA based on a smaller haplotype 
block around R304* that was fully conserved in 18 Irish pedigrees (Supp. Table S2, row E). The full 
conservation allowed us to apply an analytical formula (Donnelly, et al., 1996). The tMRCA 
distribution resulting from this first step became the prior distribution for the second step which 
used a simulation-based approach to incorporate additional conservation data of haploblocks shared 
only between subsets of pedigrees. We simulated genealogies with recombination and mutation 
using the program ms (Hudson, 2002) (Supp. Figure S1) and generated distributions of tMRCA from 
those simulations that were closest to the recombination and mutation pattern inferred from our 
haplotype data (Supp. Figure S2). Results were based on sex-averaged genetic distances for AIP and 
microsatellite loci, from HapMap v2 (The HapMap International Consortium, 2007) and Rutgers v3 
(Matise, et al., 2007) genetic maps (Supp. Table S1). Next, starting with tMRCAs randomly chosen 
from the simulated tMRCA distribution (Supp. Figure S3A, B), we took a forward simulation approach 
to generate possible trajectories for the allele frequency in the population, through binomial 
sampling. This resulted in distributions of the expected present-day number of carriers, which we 
conditioned to have at least the minimum number of R304* carriers/generation observed in our 
dataset (n=27) (Supp. Figure S3C, D). Detailed procedures, including statistical analysis are described 









Population Screening Reveals a Significantly High Carrier Frequency of the R304* Allele in 
Northern Ireland 
Several families of patients suffering from acromegaly or gigantism and carrying the Irish R304* 
allele came from a small geographical area within Mid Ulster in NI (Chahal, et al., 2011; Stals, et al., 
2011). In order to estimate the local carrier frequency of R304*, we screened a population sample of 
936 adults (Table 1), 90% of which lived in Mid Ulster.  
We identified six R304* heterozygous individuals (Supp. Table S3), corresponding to a carrier 
frequency estimate of 0.0064 (95% probability interval [CI]: 0.0027-0.013). Two related carriers, 
negative for personal or family history of PA, represented a novel R304* pedigree (Screening 1) 
(Supp. Tables S3 and S4). The remaining carriers detected through screening were two patients 
previously diagnosed with somatotrophinomas (pedigrees Sp 4 and FIPA 4) and two unaffected 
carriers from previously identified R304*-positive pedigrees Sp 4 and FIPA 1 (Supp. Tables S3 and 
S4). The R304* carrier status was significantly associated with a personal diagnosis of PA (p<0.001, 
Fisher’s exact test) and with a family history of PA (FIPA or sporadic, p<0.001, Fisher’s exact test). 
Mid Ulster screening revealed many other PA patients, either directly (R304*-negative PA patients 
participating to screening) or indirectly (non-participating PA patients mentioned as family history of 
R304*-negative screening subjects) (Supp. Table S3). 
The Greater Belfast control population sample (n=1000, Table 1) revealed one R304*-positive 
individual; corresponding to a carrier frequency of 0.001 (95% CI: 0.00011-0.0047).The carrier was 
unaffected (clinical examination, hormonal measurements and pituitary imaging), did not have a 
family history of PA, and cascade testing of relatives revealed two carriers, both unaffected (Supp. 
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In the ROI control population sample (n=2094, Table 1), no R304*-positive individuals were 
identified, corresponding to zero carrier frequency (95% CI estimate 0-0.0014). This is in accord with 
the absence/extremely low R304* carrier frequency observed in diverse population samples 
included in the Exome Aggregation Consortium (http://exac.broadinstitute.org/): two heterozygotes 
in 34,856 Europeans (0.000057) and none in 23,450 non-Europeans. The Mid Ulster carrier 
frequency was significantly higher than the ROI one (p=0.0005, Fisher’s exact test), while the Greater 
Belfast one did not differ from either ROI or Mid Ulster. 
Extrapolation of our NI R304* carrier frequency estimates (1/1000 and 6/936) and 95% CIs to the 
population of Greater Belfast (579,276) and Mid Ulster (139,011), comprising 40% of NI, according to 
the 2011 census (http://www.ninis2.nisra.gov.uk), yielded an estimated number of carriers of 1470 
(95% CI: 439-4530).  
R304* is Common in Irish Patients with Acromegaly/Gigantism 
In order to characterise the extent of R304*-related pituitary disease in Ireland, we tested for AIP 
alleles in 116 patients with acromegaly/gigantism from the two tertiary endocrine centres close to 
Mid Ulster. We identified 11 (12.6%) R304*-positive patients with somatotrophinomas in the NI 
Acromegaly Registry, Belfast, and two (6.8%) in the Dublin centre patients, while five NI (5.7%) and 
two Dublin patients (6.8%) presented other AIP variants (Supp. Table S5).  
The R304*-positive patients belonged to pedigrees FIPA 1-5 and Sp 1-6 (Supp. Table S4). The R304* 
prevalence among NI patients with somatotrophinomas was higher than that of large non-Irish 
somatotrophinoma series (Cazabat, et al., 2012; Preda, et al., 2014; Schöfl, et al., 2014; 
Tichomirowa, et al., 2011) (0-2.41%; p<0.05, Fisher’s exact test). Geographically, R304*-positive 
patients with somatotrophinomas predominated in Mid Ulster, where they, remarkably, 
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Irish R304*-positive patients with somatotrophinomas (excluding those diagnosed prospectively, 
following predictive genetic testing) displayed the known features of AIPmut-positive PAs: younger 
age at disease onset/ diagnosis, larger pituitary tumours, increased frequency of gigantism and 
familial disease, compared to AIPmut-negative patients (Table 2).  
Our investigations revealed, however, a wider range of phenotypes. While two patients, diagnosed 
as part of cascade testing in families, harboured macroadenomas and underwent surgery, two 
prospectively diagnosed R304*-positive patients had pituitary microadenomas and four patients had 
disease onset after the age of 30 years (Hernández-Ramírez, et al., 2015). Interestingly, none of the 
patients carrying other AIP variants presented a PA family history.  
All Irish R304* Pedigrees Share a Common Ancestor That Lived Approximately 2500 Years Ago 
Having identified 13 R304*-positive pedigrees through population screening and testing of 
somatotrophinoma patients in Ireland, we searched the International FIPA Consortium database for 
additional R304*-positive pedigrees and identified 10 more, resulting in a total of 23 R304*-positive 
pedigrees (Figure 2). These 10 additional pedigrees were of diverse ethnic backgrounds: six from the 
UK: one of English and  five of Irish ancestry (FIPA 6-8, Sp 7 and 18th century patient pedigrees) and 
four from other countries (Figure 2 and Supp. Table S4). In this database, we also identified 13 
AIPmut-negative Irish FIPA pedigrees (Supp. Table S6). 
By reconstructing AIP gene region STR haplotypes in these 23 pedigrees, we determined that 18 of 
them  shared a 0.2-1.95 Mbp fully conserved haploblock around R304*, as well as extended 
haploblocks covering up to the entire 8.3 Mbp genotyped region (Figure 2 and Supp. Table S1). 
These data support the existence of a recent common ancestral carrier haplotype, the Irish R304* 
founder. Fourteen of these 18 pedigrees were living in Ireland and the other four had known Irish 
ancestry. The five non-Irish pedigrees did not share significant haploblocks with the Irish ones or 
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events at this mutation-prone CpG dinucleotide (Cazabat, et al., 2012; Chahal, et al., 2011; Cuny, et 
al., 2013; Daly, et al., 2007; de Lima, et al., 2012; Leontiou, et al., 2008; Niyazoglu, et al., 2014; Occhi, 
et al., 2010; Tichomirowa, et al., 2011; Vierimaa, et al., 2006). 
The total number of Irish allele carriers was 90 (37 affected, 53 unaffected), 81 of which are 
currently alive (30 affected, 51 unaffected). Seven of the 51 unaffected living carriers (13.7%) were 
detected exclusively by population screening. The highest geographical concentration of R304* 
carriers in Ireland was observed in Mid Ulster, both for affected (somatotrophinoma) and unaffected 
individuals (Figure 1), corresponding to eight different pedigrees. A third of the Irish allele carriers 
(32%, 26/81) lived outside of Ireland: in England (21), Scotland (2), Australia (2) and Canada (1).  
To estimate the time to the most recent common ancestor (tMRCA) of the R304* carrier haplotypes 
among the Irish pedigrees, we developed a novel coalescent-based approach, combining analytical 
calculations with haplotype simulation in an Approximate Bayesian Computation (Beaumont, et al., 
2002) framework (Supp. Methods). The tMRCA estimates of the Irish R304* haplotypes were 102 
(51-200) generations - median (95% CI) - based on HapMap, and 101 (50-179) generations, based on 
Rutgers map genetic distances (Supp. Figure S3A, B). These tMRCA distributions, e.g. 51-200 
generations (HapMap-based) overlap substantially with those previously estimated: 17-150 
generations (Chahal, et al., 2011) (Pr(X>Y) = 0.79). Assuming a generation time of 25 years (Chahal, 
et al., 2011), current estimates translate to 2550 (1275-5000) years (HapMap) and 2525 (1250-4475) 
years (Rutgers). To estimate the number of living subjects carrying the Irish R304* allele, forward 
simulations conditioned on the number of observed carriers predicted 144 (30-1725) and 141 (30-
1430) carriers per generation - median (95% CI) - based on HapMap and Rutgers distances, 
respectively (Supp. Figure S3C, D). For three overlapping generations alive at present, we estimate 
the current number of carriers as 3 × 144 = 432 (90-5175; HapMap-based), corresponding to 86 (18-









Historical Irish Giants 
The medical literature, as well as Irish folklore, holds numerous descriptions of Irish giants. For some 
of these presumed pituitary gigantism individuals there is historical and medical evidence for the 
diagnosis (Supp. Table S7). We have tested DNA samples from two historical giants for AIP derived 
alleles: Charles Byrne (1761-1783), born in Mid Ulster, who carried the Irish R304* allele (Chahal, et 
al., 2011) and Cornelius Magrath (1736-1760), born in the Southern coast of Ireland and whose 
skeleton is conserved at Trinity College, Dublin (Cunningham, 1892), who was R304*-negative. Five 
additional giants related to known R304* carriers were presumed R304*-positive: Subjects 6, 7, 11, 
13 and 19 (Supp. Table S7). Two unrelated Mid Ulster screening participants, R304*-negative 
themselves, provided photographic evidence of their extremely tall relatives, whom we included as 
historical Irish giants (Figure 3 and Supp. Table S7). 
Discussion 
In this study we demonstrated that the R304* AIP allele is present in the general population of 
Ireland and its frequency varies geographically, from a high of 6/936 in Mid Ulster to 1/1000 in the 
Greater Belfast region (both in NI), while absent in a ROI population sample. These differences were 
paralleled by the geographical distribution of R304*-positive somatotrophinoma cases, representing 
a significantly higher proportion of the somatotrophinoma patient population in NI (12.6%), than in 
large published somatotrophinoma cohorts (maximum 2.41%) (Cazabat, et al., 2012; Preda, et al., 
2014; Schöfl, et al., 2014; Tichomirowa, et al., 2011), while in the ROI (Dublin centre) this proportion 
was intermediate (6.8%). Furthermore, the number of R304* carriers, both patients with 
somatotrophinomas and unaffected carriers, was highest in Mid Ulster. These data strongly support 
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R304* allele carriers were identified outside of Ireland, an observation attributable to emigration. 
Another consequence of the increased R304* carrier frequency in Ireland is that a large proportion 
(8 out of 21, 38%) of Irish FIPA families are due to R304* - the only AIPmut identified in Irish FIPA so 
far.  
We demonstrate that all 18 R304*-positive pedigrees of Irish origin identified in the study inherited 
this allele from a common ancestor, the R304*founder. In addition, we have shown that R304* in 
pedigrees of English, Indian, Romanian, US Italian, Irish and Mexican origin derives from 
independent recurrent mutational events (Chahal, et al., 2011; Ramirez-Renteria, et al., 2016). 
Founder AIPmut alleles have also been identified through haplotype analysis in Finnish (Vierimaa, et 
al., 2006), Italian (Occhi, et al., 2010), Comoros (Cuny, et al., 2013) and English (Salvatori, et al., 
2014) populations, involving the p.Q14*, p.R304*, p.G117Afs*39, and p.F269_H275dup alleles, 
respectively, but the present population frequency of all these founder alleles remains unknown. 
The refined coalescent simulation-based Approximate Bayesian Computation approach we describe 
in this paper provides a practical framework applicable to the estimation of tMRCA of identity-by-
descent alleles. Previous estimates using five pedigrees and a simpler approach indicated a more 
recent common ancestor (66 generations, 95% CI=17-150) (Chahal, et al., 2011), although the 
difference between new and previous estimates was not statistically significant (Pr(X>Y) = 0.79). 
Although the founder probably lived around 2500 years ago, many of today’s carriers are 
concentrated in a small region, suggesting a limited local migratory activity, despite significant 
emigration in recent centuries. A population bottleneck followed by re-expansion may explain the 
Mid Ulster R304* cluster, although genetic drift in a constant sized or growing population is 
consistent with observed frequencies and estimated age of this allele. Persistence of the R304* 
allele in this population may suggest the absence of, or only weak, purifying selection acting on this 
locus. While R304*-associated disease manifestations include hypopituitarism, infertility and 
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Additionally, it is possible that there were inclusive fitness effects in the unaffected carrier relatives 
of giants in the past – perhaps as a result of elevated status – that may have counterbalanced 
selective disadvantages in affected carriers. 
Identification of asymptomatic AIPmut carriers enables prospective early diagnosis of PAs, followed 
by prompt and effective treatment, with improved chances of curing the disease and preventing 
complications (Hernández-Ramírez, et al., 2015; Williams, et al., 2014). To this end, cascade testing 
of AIPmut-positive patient relatives is recommended; however, limited knowledge of family 
relations, non-disclosure of information between relatives and non-acceptance of testing may hinder 
these efforts. While carrier identification in affected individuals is now becoming standard, detection 
of unaffected carriers and their endocrine screening is a challenge for the future. Supported by 
substantial patient and community involvement, and by local media coverage, our study has created 
awareness about AIP-related disease in Ireland, a necessary precursor for improved disease 
recognition and acceptance of genetic testing. Although population screening is an unbiased 
approach to carrier identification and could detect unaffected carriers without family history of 
pituitary disease, further studies are needed to justify this approach. Our study provides a proof-of-
principle that asymptomatic R304* carriers in Ireland can be identified through population 
screening, by identifying two novel R304*-positive pedigrees comprising a relatively large proportion 
(7/52, 13.5%) of the known number of living unaffected carriers.  
Given the tMRCA-predicted number of Irish R304* carriers (432, 95% CI: 90-5175, 86 affected 
expected at 20% penetrance) and that of known living carriers (81, of which 30 affected), we 
estimate the number of undetected carriers as the difference between predicted and known 
carriers, resulting in around 351 undetected carriers, including 56 affected patients. Many of these 
undetected carriers may actually live outside of Ireland, in countries with significant Irish 
immigration, such as Great Britain, Canada and Australia, where 32% of the known living Irish allele 
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calculations by extrapolating population carrier frequency estimates (Mid Ulster and Greater Belfast) 
to regional population size (approximately 40% of NI), estimated 340 to 5138 undetected carriers, a 
range comparable to the tMRCA-predicted estimate. 
Several key features contribute to our study’s results and impact: 1) patient and general public 
involvement in its design and conduct, 2) analysis of multiple Irish general population samples and of 
a large unbiased patient cohort - the NI Acromegaly Registry, 3) analysis of the largest R304* 
pedigree collection to date, thanks to international collaboration, and 4) the incorporation of 
historical and ancient DNA data into our analyses. In comparison, studies describing other AIPmut 
founder alleles, as well as our own previous study of the Irish R304* allele, examined limited 
numbers of AIPmut pedigrees and relatively small numbers of patients and population controls, 
without providing estimates of population carrier frequencies of these alleles and their geographical 
distribution (Chahal, et al., 2011; Cuny, et al., 2013; Occhi, et al., 2010; Salvatori, et al., 2014; 
Vierimaa, et al., 2006). 
Our study also has limitations. For practical reasons, only three large Irish general population 
samples were screened for R304*. Regarding PA types included in the study, we chose to include 
only patients with somatotrophinomas, as this is largely the commonest PA type in AIPmut carriers 
and the only one for which population-level data was available. Patients with prolactinomas can also 
harbour AIP mutations, although significantly less frequently than somatotrophinomas (Cazabat, et 
al., 2012; Cuny, et al., 2013; Preda, et al., 2014; Tichomirowa, et al., 2011); the frequency of R304* in 
Irish patients with prolactinomas remains to be determined. Sampling of patients with 
somatotrophinomas from ROI was limited to the Dublin centre, based on its proximity to Mid Ulster, 
and fewer patients were analysed, compared to NI. Future studies will help to better characterise 
the R304* carrier frequency in the ROI general and PA patient populations. Not all living members of 
R304*-positive pedigrees were available for genetic and clinical testing; this is a common difficulty in 
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estimating the number of undetected allele carriers. Overall, we believe that these limitations have 
relatively little effect on our conclusions. 
Our work suggested several measures to address the challenging task of identifying the large 
number of undetected Irish R304* allele carriers, in order to improve the outcomes of PA patients. 
1) We propose R304* testing of patients of Irish descent with somatotrophinomas, especially ones 
with younger (< 30 years of age) onset, in Ireland and abroad, particularly in the Great Britain, USA, 
Canada and Australia, where large Irish immigrant populations exist. 2) Working closely together 
with patients and their communities has improved knowledge about AIP-related disease, which may 
lead to earlier recognition of disease, and hopefully increased acceptance of genetic testing. 3) 
Population screening in Ireland, especially in Mid Ulster, might be effective, but more study is 
needed regarding the psychological and economic implications, as well as further data on the clinical 
benefits of R304* screening (Hernández-Ramírez, et al., 2015). 
Our results open the way for future studies of several key aspects of AIP-related disease. The Irish 
R304* cohort is unique in having a large number of carriers sharing the same pathogenic gene 
alteration and promoter area within the fully conserved haploblock, yet pedigrees display 
differences in penetrance and patient phenotypes differ significantly. Currently, it is not known what 
influences disease penetrance in AIPmut-positive individuals. Different individual AIPmut alleles 
(Igreja, et al., 2010) or classes (e.g. truncating vs. non-truncating) (Hernández-Ramírez, et al., 2015), 
changes in gene expression regulation (Cooper, et al., 2013) and other epistatic interactions may 
each play a role, as will other genetic and environmental factors. Further genetic studies of this 
cohort could help the identification of pituitary disease-modifying genes. Follow-up of clinically-
identified and screening-detected pedigrees will provide new data about the natural history of 
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Irish folklore has numerous stories regarding Irish giants and the remains of some of these giants 
have been studied in the past (Chahal, et al., 2011; Cunningham, 1892; Frankcom and Musgrave, 
1976). Our data provides an explanation for the observation made by the pioneering anthropologist 
James C. Prichard in 1826: In Ireland men of uncommon stature are often seen, and even a gigantic 
form and stature occur there much more frequently than in this island [Britain]… We can hardly avoid 





Supp. Methods, Supp. Figures S1-S3, Supp. Tables S1-S7 and references (Austerlitz, et al., 2003; 
Bergland, 1965; Burger, et al., 2007; Carleton, 1996; Colombo, 2007; Fawcett, 1909; Frankcom and 
Musgrave, 1976; Georgitsi, et al., 2007; Lin, et al., 2007; Lynass, 1842; Oriola, et al., 2013; Prezio, et 
al., 1961; Raitila, et al., 2010; Stephens, et al., 1998; Templeton, 2006; Trivellin, et al., 2014) can be 
found in the online version of this article under “Supporting Information”.  
Acknowledgements 
We are grateful to Professor Paul Glacken, Anatomy Department, Trinity College and to Mr Gerard 
Kearns, Professor of Maxillofacial Surgery, Dublin for their help of obtaining tooth samples from the 
skeleton in Trinity College. We are very grateful to those general population screening subjects who 
provided data and materials included in Figure 3 and Supp. Table S7. We gratefully acknowledge the 
assistance of Mr. Rusko N. Slavov, Patricia and Michael Holland, and all our Mid Ulster friends who 




This article is protected by copyright. All rights reserved. 
18 
 
This work was supported by the Wellcome Trust (Clinical Training fellowship 097970/Z/11/Z to C.E.S, 
Wellcome Senior Investigator award 100719/Z/12/Z to M.G.T and Wellcome Senior Investigator 
award 098395/Z/12/A to S.E.), the European Commission Research Executive Agency (Marie Currie 
Fellowship 303006/2011 to S.R.), Barts and the London Charity (to M.K), Pfizer UK (WS 733753 to 
M.K.), Science Foundation Ireland (09/IN.1/B2640 to R.M.M.), Consejo Nacional de Ciencia y 
Tecnología (scholarship to L.C.H.R.), FIPA Patients Charity, Belfast City Hospital Charitable fund, and 
the generous support of the Holland family. 
Conflict of interest:  
MK received grant funding from Novartis and Pfizer and is a member of Medical Advisory Board of 






Austerlitz F, Kalaydjieva L, Heyer E. 2003. Detecting population growth, selection and inherited 
fertility from haplotypic data in humans. Genetics 165(3):1579-86. 
Beaumont MA, Zhang W, Balding DJ. 2002. Approximate Bayesian computation in population 
genetics. Genetics 162(4):2025-2035. 
Beckers A, Aaltonen LA, Daly AF, Karhu A. 2013. Familial isolated pituitary adenomas (FIPA) and the 
pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor 
interacting protein (AIP) gene. Endocr Rev 34(2):239-77. 




This article is protected by copyright. All rights reserved. 
19 
 
Burger J, Kirchner M, Bramanti B, Haak W, Thomas MG. 2007. Absence of the lactase-persistence-
associated allele in early Neolithic Europeans. Proc Natl Acad Sci U S A 104:3736-3741. 
Carleton W. 1996. William Carleton: the Autobiography: White Row Press Ltd. 
Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, Young J, Guiochon-Mantel A, 
Chanson P. 2012. Germline AIP mutations in apparently sporadic pituitary adenomas: 
Prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab 
97(April):1-8. 
Chahal HS, Stals K, Unterländer M, Balding DJ, Thomas MG, Kumar AV, Besser MG, Atkinson BA, 
Morrison PJ, Howlett TA, Levy MJ, Orme SM, et al. 2011. AIP mutation in pituitary adenomas 
in the 18th century and today. N Engl J Med 364(1):43-50. 
Colombo R. 2007. Dating Mutations. eLS: John Wiley & Sons, Ltd. 
Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. 2013. Where genotype 
is not predictive of phenotype: Towards an understanding of the molecular basis of reduced 
penetrance in human inherited disease. Hum Genet 132(10):1077-1130. 
Cunningham DJ. 1892. The skull and some of the other bones of the skeleton of Cornelius Magrath, 
the Irish giant. The Journal of the Anthropological Institute of Great Britain and Ireland 
21:40-41. 
Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, Tabarin A, Nunes ML, Delemer 
B, Rohmer V, Desailloud R, Kerlan V, et al. 2013. Genetic analysis in young patients with 
sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. Eur J 
Endocrinol 168(4):533-41. 
Daly AF, Vanbellinghen J-F, Khoo SK, Jaffrain-Rea M-L, Naves LA, Guitelman MA, Murat A, Emy P, 
Gimenez-Roqueplo A-P, Tamburrano G, Raverot G, Barlier A, et al. 2007. Aryl hydrocarbon 
receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis 




This article is protected by copyright. All rights reserved. 
20 
 
de Lima DS, Martins CS, Paixao BMDC, Amaral FC, Colli LM, Saggioro FP, Neder L, Machado HR, dos 
Santos ARD, Pinheiro DG, Moreira AC, Silva WA, et al. 2012. SAGE analysis highlights the 
putative role of underexpression of ribosomal proteins in GH-secreting pituitary adenomas. 
Eur J Endocrinol 167(6):759-68. 
Donnelly P, Tavaré S, Balding DJ, Griffiths RC. 1996. Estimating the age of the common ancestor of 
men from the ZFY intron. Science 272(5266):1357-9; author reply 1361-2. 
Fawcett E. 1909. Patrick Cotter-The Bristol Giant. The Journal of the Royal Anthropological Institute 
of Great Britain and Ireland 39(Jan-Jun 1909):196-208. 
Frankcom G, Musgrave JH. 1976. The Irish Giant: Gerald Duckworth & Co Ltd. 
Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Mäkinen MJ, Vierimaa O, Paschke R, Saeger W, van 
der Luijt RB, Sane T, Robledo M, De Menis E, et al. 2007. Molecular diagnosis of pituitary 
adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene 
mutations. Proc Natl Acad Sci U S A 104(10):4101-5. 
Hernández-Ramírez LC, Gabrovska P, Dénes J, Stals K, Trivellin G, Tilley D, Ferrau F, Evanson J, Ellard 
S, Grossman AB. 2015. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: 
Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab 100(9):E1242-54. 
Hudson RR. 2002. Generating samples under a Wright-Fisher neutral model of genetic variation. 
Bioinformatics (Oxford, England) 18:337-338. 
Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, Chapple JP, Trivellin G, Gueorguiev 
M, Guegan K, Stals K, Khoo B, et al. 2010. Characterization of aryl hydrocarbon receptor 
interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum 
Mutat 31(8):950-60. 
Korbonits M, Storr H, Kumar AV. 2012. Familial pituitary adenomas - who should be tested for AIP 




This article is protected by copyright. All rights reserved. 
21 
 
Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan 
S, Rowe J, Stolbrink M, Christian HC, et al. 2008. The role of the aryl hydrocarbon receptor-
interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 
93(6):2390-401. 
Lin BC, Sullivan R, Lee Y, Moran S, Glover E, Bradfield CA. 2007. Deletion of the aryl hydrocarbon 
receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. The 
Journal of Biological Chemistry 282(49):35924-32. 
Linden GJ, Linden K, Yarnell J, Evans A, Kee F, Patterson CC. 2012. All-cause mortality and 
periodontitis in 60-70-year-old men: a prospective cohort study. J Clin Periodontol 
39(10):940-6. 
Lynass B. 1842. Orange & Love Poems and Songs. Belfast. 
Matise TC, Chen F, Chen W, De La Vega FM, Hansen M, He C, Hyland FCL, Kennedy GC, Kong X, 
Murray SS, Ziegle JS, Stewart WCL, et al. 2007. A second-generation combined linkage-
physical map of the human genome. Genome Res 17:1783-1786. 
Niyazoglu M, Sayitoglu M, Firtina S, Hatipoglu E, Gazioglu N, Kadioglu P. 2014. Familial acromegaly 
due to aryl hydrocarbon receptor-interacting protein (AIP) gene mutation in a Turkish 
cohort. Pituitary 17(3):220-6. 
Occhi G, Jaffrain-Rea ML, Trivellin G, Albiger N, Ceccato F, De Menis E, Angelini M, Ferasin S, Beckers 
A, Mantero F, Scaroni C. 2010. The R304X mutation of the aryl hydrocarbon receptor 
interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or 
founder effect? J Endocrinol Invest 33(11):800-5. 
Oriola J, Lucas T, Halperin I, Mora M, Perales MJ, Alvarez-Escolá C, Paz DM-N, Díaz Soto G, Salinas I, 
Julián MT, Olaizola I, Bernabeu I, et al. 2013. Germline mutations of AIP gene in 




This article is protected by copyright. All rights reserved. 
22 
 
Preda V, Korbonits M, Cudlip S, Karavitaki N, Grossman AB. 2014. Low rate of germline AIP mutations 
in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre 
adult cohort. Eur J Endocrinol 171(5):659-66. 
Prezio JA, Griffin JE, O'Brien JJ. 1961. Acromegalic gigantism. The Buffalo giant. The American Journal 
of Medicine 31:966-76. 
Prichard JC. 1826. Researches into the physical history of mankind. London: Printed for John and 
Arthur Arch, Cornhill. 
Raitila A, Lehtonen HJ, Arola J, Heliövaara E, Ahlsten M, Georgitsi M, Jalanko A, Paetau A, Aaltonen 
LA, Karhu A. 2010. Mice with inactivation of aryl hydrocarbon receptor-interacting protein 
(Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. 
The American Journal of Pathology 177(4):1969-76. 
Ramirez-Renteria C, Hernandez-Ramirez LC, Portocarrero-Ortiz L, Vargas G, Melgar V, Espinosa E, 
Espinosa-de-Los-Monteros AL, Sosa E, Gonzalez B, Zuniga S, Unterlander M, Burger J, et al. 
2016. AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican 
experience. Endocrine. 
Reddy R, Hope S, Wass J. 2010. Acromegaly. BMJ 341:c4189-c4189. 
Salvatori R, Gabrovska P, Weber A, Quinton R, Crowne EC, Corrazzini V, Radian S, Sinha K, Lecoq A-L, 
Chanson P, Thomas MG, Baborie A, et al. Founder effect in recurring AIP mutation causing 
familial isolated pituitary adenoma syndrome. Endocrine Society's 96th Annual Meeting and 
Expo, June 21–24, 2014 – Chicago. Endocrine Reviews Supplement: ENDO 2014 Abstracts: p 
SUN-0698 (Abstract) 
Schiavi F, Demattè S, Cecchini ME, Taschin E, Bobisse S, Del Piano A, Donner D, Barbareschi M, 
Manera V, Zovato S, Erlic Z, Savvoukidis T, et al. 2012. The endemic paraganglioma syndrome 




This article is protected by copyright. All rights reserved. 
23 
 
Schöfl C, Honegger J, Droste M, Grussendorf M, Finke R, Plöckinger U, Berg C, Willenberg HS, 
Lammert A, Klingmüller D, Jaursch-Hancke C, Tönjes A, et al. 2014. Frequency of AIP gene 
mutations in young patients with acromegaly: a registry-based study. J Clin Endocrinol 
Metab 99(December):E2789-93. 
Stals K, Trivellin G, Korbonits M. 2011. AIP mutation in pituitary adenomas. N Engl J Med 
364(20):1974-5. 
Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, Winkler C, Huttley GA, 
Allikmets R, Schriml L, Gerrard B, Malasky M, et al. 1998. Dating the origin of the CCR5-
Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 
62(6):1507-15. 
Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from 
population data. Am J Hum Genet 68(4):978-89. 
Templeton AR. 2006. Population Genetics And Microevolutionary Theory. Hoboken, New Jersey: 
John Wiley & Sons, Inc. 
The International HapMap Consortium. 2007. A second generation human haplotype map of over 
3.1 million SNPs. Nature 449:851-61. 
Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, 
Elenkova A, Tabarin A, Desailloud R, Maiter D, et al. 2011. High prevalence of AIP gene 
mutations following focused screening in young patients with sporadic pituitary 
macroadenomas. Eur J Endocrinol 165:509-515. 
Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, Schernthaner-Reiter MH, Szarek E, 
Leal LF, Caberg J-H, Castermans E, Villa C, et al. 2014. Gigantism and acromegaly due to Xq26 




This article is protected by copyright. All rights reserved. 
24 
 
Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TML, 
Salmela PI, Paschke R, Gündogdu S, De Menis E, et al. 2006. Pituitary adenoma 
predisposition caused by germline mutations in the AIP gene. Science 312(5777):1228-30. 
Williams F, Hunter S, Bradley L, Chahal HS, Storr HL, Akker SA, Kumar AV, Orme SM, Evanson J, Abid 
N, Morrison PJ, Korbonits M, et al. 2014. Clinical experience in the screening and 
management of a large kindred with familial isolated pituitary adenoma due to an aryl 






Figure 1 Geographical distribution of R304* allele carriers in Ireland, compared to AIPmut-negative 
patients with somatotrophinomas. R304* carriers, unaffected (R304* unaffected, green columns) 
and patients with somatotrophinomas (R304* GH, red columns) were compared to AIPmut-negative 
patients with somatotrophinomas (AIP-neg GH, blue columns). Only subjects currently residing in 
Ireland were included; R304*-positive patients with other PA types (n=5) are not shown. The map 
was arbitrarily divided into regions separated by dotted borders, red for Mid Ulster. Ninety percent 
of the Mid Ulster screening subjects resided here, including all six R304* carriers. Each small graph 








Figure 2 Microsatellite haplotypes of chromosome 11q12.2-13.3 of R304*-positive pedigrees.  Irish 
(first two rows) and non-Irish pedigrees (third row) are shown. Marker alleles are displayed as 
amplicon sizes. Dark shading: haploblock shared between all Irish pedigrees (0.2-1.95 Mbp long); 
light shading: additional shared haploblocks. Thick horizontal lines represent AIP alleles (black = wild-
type, yellow = R304*); intervals between markers are not drawn to scale. Sp = sporadic PA. 
Haplotypes of 18th century patient, FIPA 1, 2, 3, 6, 7, FIPA UK, Romania, US (Italian) and Sp India 








Figure 3 New evidence of historical Irish giants. (A) Subject 15 (Supp. Table S7), 211cm tall, from 
Maghera, Mid Ulster, uncle of a screening participant, died of a hypertensive crisis one month after 
photograph was taken - 13th May 1918, Daily Sketch (Canadian newspaper). (B) Group of Irish 
immigrants from Garvagh (a town close to Mid Ulster) after arrival in Western Australia, 1910. At 
centre with the pole, Subject 16 (Supp. Table S7), 213 cm tall; standing far left - unrelated subject 










Table 1. Demographic parameters of Irish population samples. 





Sample type Saliva DNA Blood DNA Blood DNA 
(n=1095) 
Buccal swab DNA 
(n=999) 
Males - count 
(proportion) 
435 (46.5%) 1000 (100%) 486 (44.4%) 559 (55.9%) 
Age - years, 
median (range) 
46 (18-85) 64 (58-72) 37 (19-69) 53 (18-76) 
R304* / wt AIP 
genotype 
6 1a 0 0 
wt/wt AIP 
genotype 
930 999  1095 999 
R304* carrier 
frequency 
6/936 1/1000 0 0 
a 71 years old male, normal height, no clinical signs of pituitary disease, normal serum hormone 
levels (basal IGF-I, prolactin, and GH serum levels during the oral glucose tolerance test (GH-OGTT)), 
normal pituitary MRI examination - subsequently died of a pulmonary mesothelioma linked to 
asbestos exposure, aged 72 years; cascade testing of relatives (Screening 2 pedigree) identified two 
unaffected R304* carriers: 1M, 77 years, clinically unaffected and 1F, 42 years, clinically unaffected, 
normal pituitary MRI, random GH=4.7 ng/mL, minimal IGF-I increase (1·07 x ULN), normal PRL, GH-
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Table 2. Clinical characteristics of Irish R304*-positive somatotrophinoma patients (NI Acromegaly 
Registry, Dublin patients and FIPA Consortium database) compared to AIPmut-negative Irish patients 
with somatotrophinomas (NI and Dublin patients). 
AIP genotype Heterozygous 
NM_003977.3:c.910C>T 
Homozygous wild-type p value 
n=31 n=96 
Median age (range) at 
onset (years) 
17 (6-68) (n=29) 38.5 (14-85) (n=64) <0.0001 
Median age (range) at 
diagnosis (years) 
19.5 (7-68) (n=30) 46 (19-85) (n=95) <0.0001 
Age <30 years at 
disease onset 
27/31 (87.1 %) 21/96 (21.9 %) <0.0001 
Mean tumour size 
(mm) 
23.8 ± 10.6 (n=11) 17.2 ± 8.4 (n=43) <0.05 
Pituitary 
macroadenoma 
22/24 (91.7 %) 58/70 (82.9 %) ns 
Gigantism 18/31 (58.1 %) 7/96 (7.3 %) <0.0001 
Family history of PA 24/31 (77.4 %) 3/94 (3.2 %) <0.0001 
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